Sjögren's Disease (SjD) is a chronic, systemic immunological disorder with poorly defined initiating and driving immune pathways. While there is evidence linking the potent antiviral cytokine Interferon-alpha (IFN-α) to SjD, it has been unclear whether IFN-α directly drives the disease. A recent study presented at the European League Against Rheumatism (EULAR) 2025 Congress offers significant insights into this crucial question.
The study, led by Deborah Forbes and a team of international collaborators, sought to characterize the immune endotype of SjD patients with elevated IFN-α using two complementary cohorts. They also assessed whether IFN-α drives this SjD endotype and evaluated IFNAR1 blockade as a potential therapeutic strategy in a mouse model.
Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.
Unpacking the Methodology
The researchers employed a multifaceted approach, utilizing single-molecule ELISA and developing an interferon polyprotein score derived from Olink proteomics, to investigate the role of IFN-α in Sjögren disease. They analyzed samples from two comprehensive cohorts: the UK Primary Sjögren Syndrome Registry (UKPSSR, n = 177) and the UK Biobank Plasma Proteomics Project (n = 47606 without Sjögren, n = 257 with Sjögren, including 137 individuals sampled before diagnosis). This allowed them to determine the time course of IFN-α elevation and the associated immune endotype.
To address causality, they created a new transgenic mouse model of IFN-α overexpression where Ifna4 was overexpressed by conventional dendritic cells. This allowed the researchers to investigate whether chronically elevated IFN-α could drive the immunological features observed in SjD. Finally, they trialed IFNAR1 blockade in these mice, a novel treatment strategy for SjD, to assess its therapeutic potential.
Key Findings: A Decades-Long Driver
The study yielded compelling results that could advance our understanding of SjD pathogenesis:
IFN-a concentrations were found to be elevated in 60% of patients. IFN-a Simoa may be used to stratify Sjögren's disease.
Individuals with elevated IFN-a appeared to display distinct immunological features, characterized by cytopenias, hypergammaglobulinaemia, multiple autoantibodies, and autoimmunity against the Sjögren-specific autoantigen TRIM21/Ro52.
Polyprotein interferon signatures could be detected at least 14 years before a formal diagnosis of Sjögren's disease in the UK Biobank cohort. Plasma TRIM21 protein concentration may be used to predict an early SjD diagnosis.
This immunological endotype could be recapitulated in a novel mouse model of systemic chronic IFN-α elevation, suggesting that decades-long elevation of IFN-α may initiate and drive SjD.
The mouse model also appeared to demonstrate a response to IFNAR1 blockade, highlighting it as a potentially promising novel treatment strategy for SjD.
Why This Matters: A New Era for Sjögren Disease Management
These findings could be transformative for Sjögren's Disease research and clinical practice. They suggest that a decades-long elevation of IFN-a might initiate and drive the immune endotype of Sjögren disease. This could be a significant step towards understanding IFN-a's causal role in SjD.
The ability to detect IFN-a signatures more than a decade before diagnosis presents an unprecedented opportunity for early identification of at-risk populations. This could pave the way for proactive management, potentially influencing the progression of debilitating symptoms and systemic complications. Ultrasensitive IFN-a Simoa, combined with IFN-related polyprotein biomarkers, may provide practical tools for both disease stratification and early identification.
Furthermore, the successful blockade of IFNAR1 in the mouse model points towards a concrete therapeutic strategy. Targeting IFN-a pathways could offer a much-needed, effective treatment for a disease that has historically been difficult to manage.
While these results are compelling, and the mouse model provides strong indications of causality, it's essential to acknowledge that observational datasets, such as those used in parts of this study, have inherent biases. To definitively confirm the causal association of IFN-a with SjD and its direct role in disease progression, clinical trial confirmation will be essential. Nevertheless, this research provides invaluable insights and lays the groundwork for a new era in Sjögren's Disease management, offering hope for better outcomes for patients worldwide.
#SjögrenDisease #AutoimmuneResearch #Interferon #Rheumatology
Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.